Cardiovascular Research Foundation Oct 28 2025 Results from the first randomized clinical trial in the United States to compare a sirolimus-eluting balloon (DEB) to control group consisting of drug-eluting stent (DES) and balloon angioplasty (BA) for the treatment of bare-metal and DES in-stent restenosis (ISR) deemed DEB to be noninferior to conventional therapies.  Findings were reported today at TCT ® 2025, the annual scientific symposium of the Cardiovascular Research Foundation ® (CRF ® ).